![Stuart Peltz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stuart Peltz
President chez
PTC Therapeutics GT, Inc.
Profil
Stuart Walter Peltz is the founder of PTC Therapeutics, Inc., which was founded in 1998.
He held the title of Chief Executive Officer & Director from 2012 to 2023.
Dr. Peltz is currently a Director at PTC Therapeutics International Ltd. since 1998, President & Director at PTC Therapeutics GT, Inc., Director at PTC Therapeutics Ltd. since 2012, and Trustee at BioNJ, Inc. since 2005.
Dr. Peltz has previously worked as a Director at Biotechnology Innovation Organization from 2010 to 2015, Independent Director at Health Sciences Acquisitions Corp.
2, Professor at the University of Medicine & Dentistry of New Jersey, and Professor-Molecular Genetics & Microbiology at Robert Wood Johnson Medical School.
He holds a doctorate degree from the University of Wisconsin.
Postes actifs de Stuart Peltz
| Sociétés | Poste | Début |
|---|---|---|
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Directeur/Membre du Conseil | 01/01/2016 |
PTC Therapeutics International Ltd.
 PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | Directeur/Membre du Conseil | 01/01/1998 |
PTC Therapeutics Ltd.
 PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Directeur/Membre du Conseil | 24/02/2012 |
PTC Therapeutics GT, Inc.
 PTC Therapeutics GT, Inc. Medical SpecialtiesHealth Technology Innovates DNA therapeutics, provides long-term efficacy for patients with debilitating & fata diseases | President | - |
Anciens postes connus de Stuart Peltz
| Sociétés | Poste | Fin |
|---|---|---|
| PTC THERAPEUTICS, INC. | Fondateur | 22/03/2023 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Directeur/Membre du Conseil | 01/01/2015 |
| HEAH SCIE | Directeur/Membre du Conseil | - |
Robert Wood Johnson Medical School
 Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
University of Medicine & Dentistry of New Jersey
 University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formation de Stuart Peltz
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
70
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
University of Medicine & Dentistry of New Jersey
University of Medicine & Dentistry of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
PTC Therapeutics International Ltd.
PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | |
PTC Therapeutics GT, Inc.
PTC Therapeutics GT, Inc. Medical SpecialtiesHealth Technology Innovates DNA therapeutics, provides long-term efficacy for patients with debilitating & fata diseases | Health Technology |
Health Sciences Acquisitions Corp. 2
 Health Sciences Acquisitions Corp. 2 Financial ConglomeratesFinance Operates as a blank check company | Finance |
PTC Therapeutics Ltd.
PTC Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
